Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Study

Medication errors during treatment with new oral anticancer agents: consequences for clinical practice based on the AMBORA Study.

Schlichtig K, Dürr P, Dörje F, et al. Medication errors during treatment with new oral anticancer agents: consequences for clinical practice based on the AMBORA Study. Clin Pharmacol Ther. 2021;110(4):1075-1086. doi:10.1002/cpt.2338.

Save
Print
November 3, 2021
Schlichtig K, Dürr P, Dörje F, et al. Clin Pharmacol Ther. 2021;110(4):1075-1086.
View more articles from the same authors.

Building on prior research, this study found that medication errors are common in patients starting new oral anticancer therapy. Nearly two-thirds of these medication errors involved concomitantly administered medications (e.g., other prescribed drugs, over-the-counter medications).

Save
Print
Cite
Citation

Schlichtig K, Dürr P, Dörje F, et al. Medication errors during treatment with new oral anticancer agents: consequences for clinical practice based on the AMBORA Study. Clin Pharmacol Ther. 2021;110(4):1075-1086. doi:10.1002/cpt.2338.